# MICROCHIP CAPILLARY ELECTROPHORESIS ASSAYS AND REAGENTS

## CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Application Serial No. 17/368,377, filed July 6, 2021, and U.S. Patent Application Serial No. 17/335,756, filed June 1, 2021. Both applications are hereby incorporated by reference.

## TECHNICAL FIELD OF THE INVENTION

[0002] Aspects of the invention are generally directed to the field of capillary electrophoresis, in particular to microchip capillary electrophoresis.

## BACKGROUND OF THE INVENTION

[0003] Implementation of robust, reproducible, user-friendly technology is critical to meet the testing demands of biological products in today's Quality Control (QC) laboratories. Upgrades in technology are necessary to facilitate increased output, while continuing to generate quality analytical data and attempting to minimize the number of invalid test results and instrument-related investigations. While electrophoresis has historically been used in QC for product purity and fragmentation analysis, the methodology has transitioned from gel-based, to capillary-based, and more recently, to the microchip. Microchip Capillary Electrophoresis (MCE) allows for dramatically reduced sample analysis times, while maintaining the performance and reproducibility standards required for QC analysis (Ouimet, C., et al., Expert Opin Drug Discov., 12(2): 213-224 (2017)).

[0004] Although MCE has emerged as a promising technique with growing use in the pharmaceutical industry for characterizing biopharmaceuticals, quality control, and for drug discovery, it can be prone to assay interferences.

[0005] Thus, it is an object of the invention to provide improved MCE assays and compositions that reduce assay interferences.